MGMT PROMOTER METHYLATION STATUS INDEPENDENTLY PREDICTS PROGRESSION-FREE SURVIVAL IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT plus PCV IN HIGH-RISK LOW-GRADE GLIOMAS

著录项

• 来源
  《Neuro-Oncology》 |2017年第3期|2-3|共2页
• 作者

  Bell E. H.; Zhang P.; Aldape K.; McElroy J.; Mehta M.; Fleming J.; Liu Z.; Coons S.; Johnson D.; Chakravarti A.;

  展开▼
• 作者单位

  Ohio State Univ, Columbus, OH 43210 USA;

  NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA;

  Univ Toronto, Toronto, ON, Canada;

  Ohio State Univ, Columbus, OH 43210 USA;

  Baptist Hosp Miami, Miami, FL USA;

  Ohio State Univ, Columbus, OH 43210 USA;

  Ohio State Univ, Columbus, OH 43210 USA;

  Arizona Oncol Serv Fdn, Barrow Neurol Inst, Phoenix, AZ USA;

  St Francis Reg Med Ctr, Shakopee, MN USA;

  Ohio State Univ, Columbus, OH 43210 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词